First approved MEK/FAK combo for rare ovarian cancer seeks confirmatory Phase 3 win, while a KRAS G12D inhibitor races crowded competition for the larger prize

Bull

A positive RAMP 301 readout showing statistically significant improvement in progression-free survival (the primary endpoint) versus chemotherapy or hormonal therapy would confirm full regulatory approval, substantially expand the labeled population beyond KRAS-mutant patients, and de-risk peak revenue projections for AVMAPKI FAKZYNJA CO-PACK. This outcome would cement the combo as the definitive standard of care in recurrent LGSOC and likely trigger label expansion negotiations, supporting a meaningful re-rating of the stock.

Bear

The most significant failure mode is a primary endpoint miss in the broader KRAS-unselected population — LGSOC is a heterogeneous disease, and if the PFS benefit does not reach statistical significance across the all-comers population, the approval could be at risk of withdrawal or restricted relabeling. Secondary risks include an unexpectedly strong performance by the comparator arm (particularly hormonal therapies such as letrozole or anastrozole, which can produce durable responses in LGSOC), or a toxicity signal that complicates the benefit-risk profile in the confirmatory setting.